Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus.
Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. Radiother Oncol. 2019 Jul 02;140:131-142 Authors: Draulans C, De Roover R, van der Heide UA, Haustermans K, Pos F, Smeenk RJ, De Boer H, Depuydt T, Kunze-Busch M, Isebaert S, Kerkmeijer L Abstract Stereotactic body radiotherapy (SBRT) for prostate cancer (PCa) is gaining interest by the recent publication of the first phase III trials on prostate SBRT and the promising results of many other phase II trials. Before long term results became available, the major concern for implementing SBRT in PCa in daily clinical practice was the potential risk of late genitourinary (GU) and gastrointestinal (GI) toxicity. A number of recently published trials, including late outcome and toxicity data, contributed to the growing evidence for implementation of SBRT for PCa in daily clinical practice. However, there exists substantial variability in delivering SBRT for PCa. The aim of this topical review is to present a number of prospective trials and retrospective analyses of SBRT in the treatment of PCa. We focus on the treatment strategies and techniques used in these trials. In addition, recent literature on a simultaneous integrated boost to the tumor lesion, which could create an additional value in the SBRT treatment of PCa, was described. Furthermore, we discuss the multicenter consensus of the FLAME consortium on SBRT fo...
No abstract available
Study Shows Low Incidence of Early Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Eliminating Potential Complications and Costs Associated with Implanted Markers CLEVELAND, Aug. 19, 2019 -- (Healthcare Sales &Marketing Network) -- Vie... Devices, Oncology ViewRay, Stereotactic, MR-guided, radiotherapy, prostate cancer
The identification and accurate contouring of the intraprostatic tumor volume is a crucial step for diagnostic and therapeutic approaches in patients with primary prostate cancer (PCa). In the last decade the concept of focal radiation therapy (RT) has gained interest for patients with PCa and boosting the RT dose to the visible tumor areas within the prostate may improve treatment outcome [1,2]. Moreover, recurrent PCa after conventional RT often occurs at the site of the primary tumor [3,4]. Currently, several phase III trials (e.g.
ConclusionsThe radiation oncologist numbers have increased significantly, but unemployment remains low. Many parameters remain similar to the 2014 census, but new information has been obtained on special interest areas, leadership positions, gynae ‐oncology, inpatients, hypofractionation use, remuneration and contouring. Trainee numbers remain stable with an increased percentage satisfied with their career with much less concern about oversupply. Protected time remains an issue with contouring time and teaching emerging as a potential issue .
In this study, we used size-based filtration to isolate CTCs from the blood of 100 prostate cancer patients with high-risk localized disease. CTCs from five time points: +0, +2, +6, +12 and +24 months were analyzed. Consenting treatment-naïve patients with cT3, Gleason 8-10, or prostate-specific antigen > 20 ng/mL and non-metastatic prostate cancer were included. For all time points, we performed 3D telomere-specific quantitative fluorescence in situ hybridization on a minimum of thirty isolated CTCs. The patients were divided into five groups based on the changes of number of telomeres vs telomere lengths ...
CONCLUSION: Despite a lack of prospective data, salvage reirradiation for prostate cancer recurrence can be proposed to highly selected patients and tumours. Prospective comparative studies are needed. PMID: 31421999 [PubMed - as supplied by publisher]
Studies show similar survival in men who used testosterone after radical prostatectomy or radiation therapy compared with those who did not.Medscape Urology
ConclusionsThe results suggest that CRF exhibits both cognitive and physical characteristics. Subjective fatigue was associated with increased time required to overcome cognitive interference, but not cognitive performance accuracy. Fatigued patients exhibited decreased physical endurance and the ability to sustain maximal strength over time. These objective measures may serve as valuable tools for clinicians to detect cognitive and physical impairment associated with CRF.
Use of stereotactic body radiation therapy (SBRT) is increasing in patients with localized prostate cancer, but concerns about early and late gastrointestinal (GI) and genitourinary (GU) toxicity exist after moderately- or extremely hypofractionated radiotherapy schemes. Magnetic resonance-guided radiation therapy (MRgRT) was clinically introduced in 2014, allowing for SBRT delivery with smaller uncertainty margins and permitting daily adaptive planning. A phase II study in patients with localized prostate cancer was performed to study early GI and GU toxicity following SBRT using MRgRT.
CONCLUSION: Hemiablation HIFU is an alternative to whole gland therapy in patients with unilateral radio- recurrent prostate cancer, which offers limited urinary and rectal morbidity, and preserves functional outcomes. LEVEL OF EVIDENCE: 3. PMID: 31400963 [PubMed - as supplied by publisher]